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introduction: Impaired high-density lipoprotein (HDL) levels and antioxidant functional-
ity of HDL, mainly attributed to a decreased paraoxonase-1 (PON1) functionality, have 
been described in autoimmune conditions. In this setting, a role for humoral response in 
cardiovascular disease is emerging. This study evaluates the role of immunoglobulin G 
(IgG) antibodies against HDL and disease-related autoantibodies on HDL dysfunction in 
immune-driven diseases.
Methods: Serum IgG anti-HDL antibodies, PON1 activity, and total antioxidant capacity 
(TAC) were quantified in 381 patients with different immune-driven diseases [18 mixed 
connective tissue disease (MCTD), 35 primary Sjögren syndrome (pSS), 38 systemic 
sclerosis (SSc), 33 ANCA-associated vasculitis (AAV), 60 diabetes mellitus 1, 29 autoim-
mune B12 deficiency/pernicious anemia, 29 primary biliary cirrhosis, 46 IBD/Crohn, 54 
IBD/UC, and 39 celiac disease (CD)] and 138 healthy controls.
results: IgG anti-HDL antibodies were increased in MCTD, pSS, AAV, and inflammatory 
bowel disease (IBD) [Crohn and ulcerative colitis (UC)], even after correcting for total 
IgG levels, but not in organ-specific autoimmune diseases. Anti-HDL antibodies were 
negatively associated with PON1 activity in MCTD (r = −0.767, p < 0.001) and AAV 
(r = −0.478, p = 0.005), whereas both anti-HDL and anti-neutrophil cytoplasm antibod 
levels were related to an impaired PON1 activity and TAC in IBD/UC. In SSc, anti-cen-
tromere antibodies correlated PON1 activity. anti-Saccharomyces cerevisiae antibodies 
levels were negatively associated with PON1 activity (r = −0.257, p = 0.012) and PON1/
TAC ratio (r = −0.261, p = 0.009) in IBD/Crohn. HDL dysfunction in CD was only related 
to anti-transglutaminase levels.
conclusion: IgG anti-HDL antibodies and HDL dysfunction are common hallmarks of 
systemic autoimmunity. Anti-HDL and disease-related autoantibodies account for the 
HDL antioxidant dysfunction in immune-driven conditions, mainly in systemic autoim-
mune disorders.
Keywords: anti-hDl, autoantibodies, high-density lipoprotein, antioxidant, autoimmunity, cardiovascular
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inTrODUcTiOn
Systemic autoimmune disorders are commonly associated with 
an increased risk of cardiovascular disease (CVD) occurrence 
compared to the general population (1, 2). Different studies 
showed that traditional CV risk factors fail to fully account for 
this increased CV morbidity (3, 4), whereas chronic inflamma-
tion and immune dysregulation are thought to play a role (5, 6). 
However, the actual mediators remain unknown.
High-density lipoproteins (HDL) are pivotal in the preven-
tion of atherosclerosis. HDL promote endothelial homeostasis 
by their role in the reverse cholesterol transport as well as by 
their antioxidant and anti-inflammatory activities (7). Altered 
levels of HDL and blood lipids have been described in systemic 
autoimmune diseases, and a paradoxical effect on CV risk (the 
so-called “lipid paradox,” whereby low lipid levels are associ-
ated with increased CV risk) is widely accepted (8, 9), although 
poorly understood. Similarly, impaired HDL functionality, 
mainly due to a decreased enzymatic activity of the calcium-
dependent esterase paraoxonase 1 (PON1), has been reported 
in these conditions (10–12). Due to their association with CVD 
development, understanding changes in lipid levels and/or 
functionality as well as the underlying mechanisms, represents 
a major research topic.
In recent years, the hypothesis that autoantibodies can have a 
role in the pathogenesis of CVD has emerged from clinical stud-
ies (13–17). However, contradictory results (18, 19) suggest that 
although the humoral immune response can be linked to CVD 
development, the specific autoantibodies and their targets are yet 
to be elucidated.
Recent findings point to a detrimental interplay between 
autoantibodies and lipid profiles. Autoantibodies targeting 
HDL lipoproteins [immunoglobulin G (IgG) anti-HDL anti-
bodies] and their components have been described in systemic 
lupus erythematosus (SLE) and rheumatoid arthritis (RA). 
Initially described in association with disease activity and 
antioxidant features (20, 21), our group has recently revealed 
an association among anti-HDL antibodies, lipid profiles, and 
lipoprotein functionality in SLE and RA (22–24). Interestingly, 
these antibodies were not related to traditional CV risk factors, 
hence confirming its role as non-traditional CV risk factors in 
this setting. Thus, these autoantibodies may be considered as 
orchestrators of the interactions between immunity and altered 
lipid profiles. However, with anti-HDL being documented in 
RA and SLE with similar clinical outcomes, these findings pose 
the question as whether these antibodies may be also detected 
in other immune-driven conditions.
We hypothesize that the HDL dysfunction associated with 
anti-HDL antibodies can be a common feature in immune-
mediated diseases rather than a specific phenomenon of a single 
disease. Thus, the overarching aim of this study is to analyze 
the levels of anti-HDL antibodies in a broad range of differ-
ent immune-mediated conditions. The specific objectives are 
(i) to analyze the levels of IgG anti-HDL antibodies in different 
immune-driven diseases, from systemic rheumatic to organ-
specific autoimmune conditions, (ii) to study the associations 
between anti-HDL antibodies, lipid profiles, and HDL func-
tionality, and (iii) to analyze the interactions between the IgG 
anti-HDL–HDL axis with clinical features and disease-related 
autoantibodies among diseases.
MaTerials anD MeThODs
Patients and controls
This study involved a cross-sectional sample of 381 individuals 
with different immune-mediated diseases recruited from the 
department of Clinical Immunology at the Hospital Universitario 
Central de Asturias (Asturias, Spain). Patients were recruited 
after a clinical appointment in the respective clinical depart-
ments (Internal Medicine, Rheumatology, Gastroenterology and 
Nephrology) at the same institution. Fasting blood samples, taken 
during the routine clinical examination at the clinical depart-
ments, were sent to the department of Clinical Immunology 
to be immediately processed and stored at −80°C until further 
analyses. A fresh aliquot was used for the determination of the 
panel of the disease-related autoantibodies for each condition 
(Table 1).
Disease diagnoses were confirmed by the corresponding 
consultant from each clinical department according to validated 
criteria: Alarcón-Segovia criteria for mixed connective tissue 
disease (MCTD) (25), 2002 EULAR classification criteria for 
primary Sjögren Syndrome (pSS) (26), 1980 ACR criteria for 
Systemic Sclerosis (SSc) (27), 1990 ACR criteria for the clas-
sification of vasculitis (28), criteria for primary biliary cirrhosis 
(29), American Diabetes Association criteria for type 1 diabetes 
mellitus (DM1) (30), classification criteria for gastritis and 
pernicious anemia (B12/PA) (31), Vienna/Montreal criteria 
for Inflammatory Bowel Diseases (IBD) (32, 33), and World 
Gastroenterology Organization guidelines for celiac disease 
(CD) (34).
A group of 138 matched healthy individuals (without any 
disease or treatment at the time of sampling) from the same 
population was simultaneously recruited as the healthy control 
(HC) group. Automated analysis of serum lipids was performed 
on fresh blood samples from all of the participants. Study approval 
was obtained from the Institutional Review Board (Comité de 
Ética Regional de Investigación Clínica) in compliance with the 
Declaration of Helsinki. All participants gave written informed 
consent prior to their inclusion in the study.
Abbreviations: AAV, ANCA-associated vasculitis; AMA, anti-mitocondrial 
antibodies; ANA, antinuclear antibodies; ANCA, anti-neutrophil cytoplasm anti-
bodies; anti-dsDNA, anti-double strand DNA antibodies; anti-GAD, anti-glutamic 
acid decarboxylase antibodies; anti-GPC, anti-gastric parietal cell antibodies; anti-
IA2, anti-islet antigen 2 antibodies; anti-IF, anti-intrinsic factor antibodies; anti-
MPO, anti-myeloperoxidase; anti-PR3, anti-proteinase 3 antibodies; anti-RNP, 
anti-ribonucleoprotein antibodies; anti-Scl70, anti-DNA Topoisomerase I anti-
bodies; anti-TGA, anti-transglutaminase antibodies; ASCA, anti-Saccharomyces 
cerevisiae antibodies; AU, arbitrary units; CD, celiac disease; B12, autoimmune 
B12 deficiency; CV, cardiovascular; DM1, diabetes mellitus 1; HDL, high-density 
lipoprotein; IBD, inflammatory bowel disease; IgG, immunoglobulin G; MCTD, 
mixed connective tissue disease; PA, pernicious anemia; PBC, primary biliary 
cirrhosis; PON1, paraoxonase 1; pSS, primary Sjögren syndrome; SSc, systemic 
sclerosis; TAC, total antioxidant capacity; UC, ulcerative colitis.
Table 1 | Demographic features and blood lipid profiles of the individuals entered in this study.
hc McTD pss ssc aaV ibD/Uc ibD/crohn cD Pbc DM1 b12/Pa
n 138 18 35 38 33 54 46 39 29 60 29
Demographic parameters
Female, n (%) 108 (78.2) 15 (83.3) 33 (94.2) 34 (89.4) 15 (45.4) 29 (53.7) 25 (54.3) 25 (64.1) 25 (86.2) 30 (50.0) 25 (86.2)
Age [mean  
(range)]
51.48 
(25.33–80.00)
49.22 
(21.00–84.00)
56.17 
(28.00–79.00)
59.39 
(29.00–87.00)
64.15 
(27.00–85.00)
48.83 
(19.00–83.00)
52.00 
(18.00–85.00)
38.20 
(18.00–77.00)
58.00 
(40.00–84.00)
42.83 
(18.00–71.00)
61.37 
(29.00–85.00)
blood lipid profiles, mean ± sD
Total  
cholesterol  
(mg/dl)
201.01 ± 35.22 167.51 ± 31.29 184.35 ± 36.22 190.34 ± 36.92 202.02 ± 37.98 191.67 ± 40.87 174.84 ± 44.19 173.94 ± 36.08 195.12 ± 47.94 187.90 ± 34.84 187.89 ± 50.31
HDL- 
cholesterol  
(mg/dl)
59.67 ± 14.21 48.98 ± 10.95 62.20 ± 15.36 57.43 ± 16.85 61.40 ± 22.51 57.17 ± 17.60 49.05 ± 15.40 51.95 ± 16.60 57.33 ± 20.88 59.98 ± 17.61 56.81 ± 16.66
LDL- 
cholesterol  
(mg/dl)
123.56 ± 31.55 96.02 ± 32.22 113.16 ± 66.96 111.23 ± 32.51 115.68 ± 29.56 75.15 ± 36.07 66.78 ± 39.77 105.72 ± 34.67 107.14 ± 38.47 106.66 ± 31.57 111.42 ± 43.50
TC/HDL ratio 3.57 ± 1.02 3.52 ± 0.83 3.10 ± 0.91 3.51 ± 1.01 3.60 ± 1.18 3.61 ± 1.23 3.78 ± 1.14 3.70 ± 1.47 3.94 ± 2.17 3.39 ± 1.22 3.47 ± 1.09
Triglycerides  
(mg/dl)
84.47 ± 36.69 101.77 ± 44.88 89.8 5 ± 64.14 109.24 ± 51.95 133.91 ± 65.28 98.29 ± 50.04 117.52 ± 56.39 83.07 ± 46.18 113.67 ± 73.74 107.12 ± 96.93 122.58 ± 61.40
Continuous variables are summarized as mean ± SD, unless otherwise stated. Categorical variables are summarized as n or n (%), as indicated.
AAV, ANCA-associated vasculitis; CD, celiac disease; DMI, diabetes mellitus 1; HDL, high density lipoprotein; MCTD, mixed connective tissue disease; PBC, primary biliary cirrhosis; pSS, primary Sjögren syndrome; SSc, systemic 
sclerosis; HC, healthy control.
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analysis of autoantibodies
Antinuclear, anti-neutrophil cytoplasm, and anti-mitochondria 
antibodies [antinuclear antibodies (ANA), anti-neutrophil cyto-
plasm antibodies (ANCA), and anti-mitocondrial antibodies] 
were determined by indirect immunofluorescence on Hep-2 
cells, ethanol/formalin fixed neutrophils, and rat liver/stomach/
kidney (INOVA Diagnostics, San Diego, CA, USA), respectively. 
Anti-double strand DNA antibodies, myeloperoxidase, protein-
ase 3 (PR3), and transglutaminase IgA (TGA) antibodies were 
quantified in a chemiluminescent analyzer (ZENIT RA, Menarini 
Diagnostics, Firenze, Italy). ENA specificities (SSA/Ro, SSB/
La, RNP, Sm, and Scl-70) were identified by line blot analysis 
(Euroimmun, Lübeck, Germany). An ELISA technique was used 
to quantify antibodies against gastric parietal cells, intrinsic 
factor (Menarini Diagnostics), glutamic decarboxylase (GAD), 
tyrosine phosphatase-related islet antigen 2 (IA2) (RSR Ltd., 
Cardiff, UK), and Saccharomyces cerevisiae [anti-Saccharomyces 
cerevisiae antibodies (ASCA)] (Wieslab, Malmö, Sweden).
Determination of igg anti-hDl antibodies
Serum levels of IgG anti-HDL antibodies were measured by 
ELISA techniques as previously described (23, 35). Briefly, 
96-well NUNC Maxisorp plates were overnight coated with 
20 µg/ml human HDL (Sigma Aldrich, Germany) in 70% etha-
nol (test half) or ethanol alone (control half). After a blocking 
for 1  h (PBS 1% BSA), plates were washed and 1:50-diluted 
serum samples were incubated for 2  h at room temperature. 
Then, plates were washed with TBS (three times) and an 
alkaline phosphatase-conjugated anti-human IgG (1:1,000) 
(Immunostep, Spain) was added. One-hour later, the plates 
were washed twice with TBS and 1 mg/ml p-nitrophenylphos-
phate (Sigma) in dietanolamine buffer was added as substrate. 
Absorbance at 405  nm was recorded and signal from the 
control half of the plate was subtracted to that of the test half. 
Anti-HDL arbitrary units (AU) were calculated for each sample 
according to the standard curves (from pooled sera diluted 1:16 
to 1:512).
Total IgG was quantified by conventional ELISA techniques 
and AU values obtained from the anti-HDL ELISA were cor-
rected using total IgG levels (anti-HDL/IgG). To evaluate the 
burden of IgG anti-HDL positivity, the cutoff for an individual to 
be classified as “positive” was set using the 90th percentile found 
in the HC population (=90.78) (23, 35).
assessment of POn1 activity
Serum PON1 activity was assessed according to the method 
described by Eckerson et al. with little modifications as previously 
described (23). Briefly, 300 µl of freshly prepared 1 mM paraoxon 
(Sigma) in 50 mM glycine buffer containing 1 mM CaCl2 (pH 10.5) 
was incubated with 7.5 µl of serum samples in 96-well NUNC 
Maxisorp plates for 20 min at 37°C. Production of p-nitrophenol 
was monitored at 405 nm. A unit of PON1 activity was expressed 
as micromoles of p-nitrophenol produced per minute and per 
milliliter of serum. Quality controls were included in each plate 
to correct for interassay variations.
analysis of Total antioxidant capacity 
(Tac)
Serum TAC was measured by means of a colorimetric assay 
based on the cupric reducing antioxidant capacity (CUPRAC 
method). A commercial kit (TAC Assay Kit, Sciencell Research 
Laboratories) was used following the instructions provided by the 
manufacturer. Serum TAC was expressed as millimolar Trolox 
equivalent units (mM T-Eq).
statistical analysis
Continuous variables were summarized as median (interquartile 
range) or mean ±  SD, whereas n (%) was used for categorical 
ones. Differences among groups were analyzed by Kruskal–Wallis 
(with Dunn–Bonferroni correction for multiple comparisons 
tests) or Mann–Whitney U tests, as appropriated. Spearman’s 
rank test was used for correlations, whereas χ2 tests were 
performed to analyze the distribution of categorical variables. 
Multiple regression analyses were carried out to evaluate the 
potential simultaneous effect of different independent factors on 
a dependent variable. Variables were log-transformed to achieve 
normal distribution prior to multiple regression analyses and B 
coefficients and 95% confidence intervals (CI) were computed. 
Significance was assumed at a p-value of <0.050. All statistical 
analyses were performed under SPSS 22.0 and GraphPad Prism 
5.0 for Windows.
resUlTs
levels of igg anti-hDl antibodies  
in immune-Mediated Diseases
The levels of IgG anti-HDL antibodies were quantified in serum 
samples from 138 HC and 381 patients with different immune-
driven diseases (Table 1). Levels of IgG anti-HDL antibodies 
were found to be increased in MCTD [40.98 (164.65) AU, 
p <  0.001], pSS [19.72 (51.38) AU, p =  0.012], AAV [23.90 
(42.26) AU, p =  0.030], CD [11.23 (31.63) AU, p =  0.050], 
IDB/Crohn [12.16 (53.03) AU, p = 0.020], and IBD/UC [17.34 
(79.79) AU, p < 0.001] patients compared to those in HC [2.44 
(12.92) AU]. Equivalent results were obtained when anti-HDL 
levels were corrected for total IgG levels (anti-HDL/IgG) 
(Figure  1A). According to the established cutoff, increased 
prevalence of anti-HDL positivity was found in MCTD, SS, 
AAV, IBD/Crohn, and IBD/UC (Figure  1B). IgG anti-HDL 
antibodies were not associated with age (r = −0.027, p = 0.765) 
nor with gender (p = 0.136) in HC or patients (both p > 0.050). 
Since a differential distribution of gender was observed in AAV, 
DM1, CD, IBD/C, and IBD/UC, a subgroup of HC with paired 
gender distribution was selected (Table 2). Differences in anti-
HDL levels using this control population remained statistically 
significant (Figure S1 in Supplementary Material), therefore 
excluding the possibility that gender distribution could be a 
confounding factor.
Finally, the potential associations between anti-HDL/IgG 
levels and the blood lipid profile were studied. However, anti-
HDL/IgG was not correlated with total cholesterol (r = −0.023, 
Table 2 | Subgroup paired analysis of the healthy control (HC) group.
hc
n 76
Gender (f/m) 43/33
Age [mean (range)] 52.91 (25.33–73.00)
Total cholesterol (mg/dl) 203.17 ± 32.01
HDL-cholesterol (mg/dl) 55.05 ± 13.32
LDL-cholesterol (mg/dl) 125.46 ± 27.52
TC/HDL ratio 3.57 ± 1.02
Triglycerides 77.85 ± 32.63
Anti-HDL/IgG, 90th P 87.37
No differences in gender were observed between this HC subgroup and ANCA-
associated vasculitis (p = 0.285), DMI1 (p = 0.445), celiac disease (CD) (p = 0.437), 
inflammatory bowel disease (IBD) (p = 0.810), and IBD/UC patients (p = 0.745). This 
group was comparable in terms of lipid profile and anti-high-density lipoprotein (HDL) 
levels to the whole HC population (Table 1). Continuous variables are summarized as 
mean ± SD, unless otherwise stated. Categorical variables are summarized as n.
FigUre 1 | Immunoglobulin G (IgG) anti-high-density lipoprotein (HDL) antibodies in different autoimmune conditions. (a) Serum levels of anti-HDL/IgG antibodies in 
different autoimmune conditions and healthy control (HC). Each dot represents one subject, whereas horizontal bars represent the median value and gray boxes 
delimit 25th and 75th percentiles. Horizonal dashed lines represents the value of 90th percentile of anti-HDL/IgG in the HC group (=90.78). Differences against HC 
group were assessed by Kruskal–Wallis test and Dunnett correction for multiple comparisons test. (b) Positivity of anti-HDL antibodies in autoimmune conditions. 
The frequency of individuals classified as anti-HDL positive (using the 90th percentile found in the HC group as reference) is shown for each condition between 
parenthesis and represented as the black section of each graph. Differences compared to the HC were assessed by χ2 tests. Statistical significance is indicated as 
*p < 0.05, **p < 0.010, and ***p < 0.001.
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p = 0.801), nor with HDL (r = −0.002, p = 0.979) or LDL fractions 
(r = −0.035, p = 0.703) in HC, neither among immune-mediated 
diseases (all p < 0.050).
All these results revealed a specific increase in IgG anti-HDL 
antibodies in patients with systemic immune-mediated disorders, 
but not in organ-specific conditions.
igg anti-hDl antibodies and POn1 
activity
We wondered whether IgG anti-HDL antibodies could be associ-
ated to a decreased HDL functionality. To test this hypothesis, 
serum PON1 activity and TAC were measured.
Serum PON1 activity was decreased in MCTD, SSc, AAV, CD, 
IBD/Crohn, and IBD/UC patients (Figure  2A), suggesting an 
overlap between impaired PON1 activity and increased anti-HDL 
positivity. Interestingly, anti-HDL/IgG antibodies were negatively 
correlated with PON1 activity in MCTD, AAV, and IBD/UC 
(Figure 2B).
Total antioxidant capacity was decreased in patients with gut-
related immune conditions (Figure 2C). Remarkably, anti-HDL 
levels were only associated with TAC in IBD/UC (r = −0.343, 
p = 0.011). However, a positive correlation between TAC and 
PON1 activity was observed in IBD/Crohn patients (r = 0.360, 
p =  0.014). The analysis of the PON1/TAC ratio (Figure 2D) 
revealed a different contribution of the PON1 activity to the 
total antioxidant status, being lower in CD.
Therefore, our findings demonstrate an antioxidant dysfunc-
tion in some immune-driven diseases. IgG anti-HDL antibodies 
may account for the impaired PON1 activity in some systemic 
conditions.
FigUre 2 | Paraoxonase 1 (PON1) activity, total antioxidant capacity (TAC), and PON1/TAC ratio in autoimmune conditions. (a) Serum PON1 activity, (c) serum 
TAC, and (D) PON1/TAC ratio were evaluated in autoimmune patients and healthy control (HC). Each dot represents one subject, whereas horizontal bar represents 
the median value and gray boxes delimit 25th and 75th percentiles. Differences against HC group were assessed by Kruskal–Wallis test and Dunnett correction for 
multiple comparisons test. Statistical significance is indicated as *p < 0.05, **p < 0.010, and ***p < 0.001. (b) Association between anti-high-density lipoprotein/IgG 
and serum PON1 activity in mixed connective tissue disease (MCTD), ANCA-associated vasculitis (AAV), and IBD/UC patients. Correlations were assessed by 
Spearman rank’s test.
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igg anti-hDl antibodies–POn1 axis  
in systemic immune-Driven Diseases: 
involvement of Disease-related 
autoantibodies
Since a notable heterogeneity was found among immune-driven 
diseases not only concerning the IgG anti-HDL levels observed 
but also regarding the association between the latter and serum 
PON1 activity, we aimed to evaluate whether disease-related 
autoantibodies (Table 3) can explain these discrepancies.
Anti-HDL/IgG antibodies nor PON1 activity were associa-
ted with disease-related autoantibodies in MCTD, pSS, or AAV. 
Interestingly, a different picture was observed in SSc patients. No 
differences in IgG anti-HDL/IgG antibodies (p = 0.334) or PON1 
activity (p = 0.253) were found between limited (n = 29) or dif-
fuse SSc (n =  6) patients. However, ANA titer was negatively 
correlated with serum PON1 activity (r = −0.404, p = 0.012), 
this correlation being restricted to patients with a centromere 
pattern (Figure 3A). Additionally, SSc patients positive for anti-
DNA Topoisomerase I antibodies exhibited diminished TAC 
compared to their negative counterparts [4.21 (0.60) vs 5.47 
(1.39) mM T-Eq, p = 0.042].
Concerning organ-specific conditions, anti-HDL/IgG anti-
bodies paralleled those of anti-glutamic acid decarboxylase anti-
bodies (anti-GAD) (r = 0.246, p = 0.068) in DM1. Thus, anti-HDL 
positivity was slightly higher in anti-GAD positive DM1 patients 
(3/34, 26.4%) compared to their anti-GAD negative counterparts 
(3/22, 13.6%). Moreover, serum PON1 activity exhibited a non-
significant negative trend with IA2 titer (r = −0.237, p = 0.079). 
No differences between DM1 recruited at onset (n = 6) and those 
recruited in later stages were found.
Gut-related conditions exhibited disease-specific patterns 
regarding the associations between the IgG anti-HDL-PON1 axis 
and disease-related antibodies. In Crohn patients, ASCA levels 
were associated with PON1 activity (r = −0.257, p = 0.012) and 
PON1/TAC ratio (r = −0.261, p = 0.009). On the other hand, PON1 
activity was negatively correlated to ANCA titer (r = −0.382, 
p = 0.006) in IBD/UC. A clear additive effect on PON1 impair-
ment was observed when both ANCA and anti-HDL autoanti-
bodies were present (Figure 3B). This negative effect on PON1 
activity was confirmed by multiple regression analysis: ANCA 
(B[95% CI], p: −0.326 [−0.284, −0.023], p = 0.022) and anti-HDL 
(−0.273 [−0.280, −0.002], p < 0.050). A similar detrimental effect 
was also observed for TAC (Figure 3B). Finally, PON1 activity 
FigUre 3 | Anti-high-density lipoprotein (HDL) antibodies, disease- 
related autoantibodies, and paraoxonase 1 (PON1) activity. (a) Association 
between anti-centromere titer and serum PON1 activity in systemic 
sclerosis patients. (b) Association between anti-HDL and anti-neutrophil 
cytoplasm antibodies (ANCA) positivity and PON1 activity and serum total 
antioxidant capacity (TAC) in IBD/UC patients. (c) PON1 activity, serum 
TAC, and HDL levels in celiac disease (CD) patients recruited at diagnosis 
(DX) or those under a strict gluten-free diet (GF). Each dot represents one 
subject, whereas horizontal bars represent the median value and gray 
boxes delimit 25th and 75th percentiles. Differences were assessed by 
Kruskal–Wallis test and Dunn–Bonferroni correction for multiple 
comparisons test. Statistical significance is indicated as *p < 0.05, 
**p < 0.010, and ***p < 0.001.
Table 3 | Disease-related autoantibodies in the individuals entered in this study.
autoantibodies Frequency
Mixed connective 
tissue disease 
(n = 18)
Antinuclear antibody (ANA) 18 (100.0)
Anti-SSA 6 (33.3)
Anti-ribonucleoprotein antibodies 
(Anti-RNP)
18 (100.0)
Anti-double strand DNA antibodies 
(anti-dsDNA)
5 (27.7)
Titer, mean ± SD 27.58 ± 57.49
Primary Sjögren 
syndrome (n = 35)
ANA 32 (91.4)
Anti-SSA 27 (77.1)
Anti-SSB 15 (42.8)
Anti-RNP 2 (5.7)
Anti-dsDNA 3 (8.5)
Titer, mean ± SD 47.30 ± 3.60
Anti-centromere 1 (2.8)
Systemic sclerosis 
(n = 38)
ANA 38 (100.0)
Anti-SSA 2 (5.2)
Anti-SSB 1 (2.6)
Anti-RNP 0 (0.0)
Anti-dsDNA 2 (5.2)
Titer, mean ± SD 48.75 ± 14.21
Anti-DNA topoisomerase I antibodies 7 (18.4)
Anti-centromere 28 (73.6)
1/320 1 (3.5)
1/640 12 (42.8)
1/1280 10 (35.7)
1/2560 5 (17.8)
ANCA-associated 
vasculitis (n = 33)
ANA 8 (24.2)
Anti-proteinase 3 antibod 13 (39.4)
Titer, mean ± SD 116.28 ± 68.22
Anti-myeloperoxidase 12 (36.4)
Titer, mean ± SD 46.28 ± 49.59
IBD/UC (n = 54) ANA 5 (9.2)
p-ANCA 29 (55.7)
1/80 8 (15.3)
1/160 11 (21.1)
1/320 6 (11.5)
>1/650 4 (7.7)
IBD/Crohn (n = 46) ANA 7 (15.2)
p-ANCA 3 (6.5)
anti-Saccharomyces cerevisiae 
antibodies
26 (60.8)
Titer, mean ± SD 62.47 ± 49.78
Celiac disease 
(n = 39)
ANA 5 (12.8)
Anti-transglutaminase antibodies 33 (84.6)
Titer, mean ± SD 101.57 ± 79.48
Primary biliary 
cirrhosis (n = 29)
ANA 21 (72.4)
Anti-centromere 7 (24.1)
Anti-mitocondrial antibodies 26 (89.6)
Diabetes mellitus 1 
(n = 30)
ANA 8 (13.3)
Anti-glutamic acid decarboxylase 
antibod
34 (56.6)
Titer, mean ± SD 671.74 ± 718.59
Anti-islet antigen 2 antibodies (31.6)
Titer, mean ± SD 912.77 ± 1,465.64
autoantibodies Frequency
B12/PA (n = 29) ANA 3 (10.3)
Anti-gastric parietal cell antibodies 23 (79.3)
Titer, mean ± SD 54.09 ± 19.40
Anti-intrinsic factor antibodies 7 (24.1)
Titer, mean ± SD 134.25 ± 48.75
The levels of different panels of disease-related autoantibodies were tested in the 
individual recruited for this study according to validated guidelines. The frequency of 
the autoantibodies was indicated as n (%) referred to the total of patients for each 
disease. The titers of some autoantibodies were expressed as mean ± SD or n (%) 
among patients positive for the corresponding antibody.
(Continued )
Table 3 | Continued
7
Rodríguez-Carrio et al. Anti-HDL and HDL Dysfunction in Immune-Driven Diseases
Frontiers in Medicine | www.frontiersin.org April 2018 | Volume 5 | Article 114
and TAC were strongly decreased in CD, an association among 
anti-transglutaminase antibodies (anti-TGA) antibodies, HDL 
levels and antioxidant features being disclosed. Patients recruited 
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at disease diagnosis (DX, n = 24) exhibited notable differences 
in serum PON1, TAC, and HDL levels compared with those 
with a longer disease duration following a strict gluten-free diet 
(GF, n  =  15) (Figure  3C). These differences paralleled those 
found with anti-TGA levels [DX: 125.00 (178.78) vs GF: 15.80 
(90.52) IU, p = 0.019].
Overall, anti-HDL IgG were not associated with disease-related 
autoantibodies, thus reinforcing the relevance of anti-HDL as 
novel biomarkers. Interestingly, anti-HDL and disease-related 
autoantibodies exhibited different associations with PON1 activ-
ity, HDL and PON1 among the different conditions.
DiscUssiOn
Although a growing body of evidence supports a role for humoral 
immunity in CVD, the underlying mediators remain unclear. 
The results presented in this study point to the autoantibodies 
against HDL as the missing link between humoral response, 
lipoprotein dysfunction and oxidative stress in immune-driven 
diseases. Anti-HDL antibodies can be proposed as an explana-
tion for the elusive hypothesis of the “lipid paradox.” Although 
initially described as a consequence of the inflammatory burden, 
further studies revealed that inflammation itself cannot totally 
account for the alteration in the lipid profile (9), thus suggest-
ing the involvement of additional mediators. More recently, the 
concept of “lipid paradox” has been expanded to “HDL dysfunc-
tion,” since not only the levels but also the HDL functionality 
has been found altered in inflammatory diseases (36, 37). Thus, 
anti-HDL antibodies emerge as potential orchestrators of this 
phenomenon. Because of the role of lipoprotein dysfunction 
in CVD, a role for anti-HDL antibodies as biomarkers may be 
expected.
anti-hDl antibodies in immune-Mediated 
Diseases: systemic vs Organ-specific 
conditions
A remarkable finding from our study is the difference in anti-
HDL levels among different immune-driven diseases. The highest 
anti-HDL levels were found in systemic autoimmune rheumatic 
conditions (MCTD, pSS, and AAV) as well as in IBD, whereas 
increased anti-HDL levels were not observed in organ-specific 
autoimmune diseases. These results are in line with previous 
studies from our group and others, revealing a similar prevalence 
in RA and SLE (23, 24, 35).
Among systemic diseases, MCTD exhibited the highest preva-
lence of anti-HDL positivity. Interestingly, although CVD occur-
rence is increased in MCTD (38), the responsible mechanisms 
are unknown. Increased levels of disease-related autoantibodies 
have been found in MCTD patients with CVD (39, 40), thereby 
suggesting a role for humoral immune response in the CVD 
development in MCTD. However, these studies failed to disclose 
an association between these autoantibodies and markers of CVD. 
Instead, decreased apolipoprotein (Apo) A1, but not Apo B, was 
associated to impaired vascular homeostasis (39), stressing the 
relevance of HDL particles. Our results show a clear association 
between anti-HDL antibodies and the impaired PON1 activity 
in MCTD, thus strengthening the role of these autoantibodies 
in this condition. Moreover, MCTD exhibited greater alterations 
in surrogate markers of CVD than other connective tissue dis-
orders, such as pSS or SSc (41) and different mechanisms of 
vascular damage between MCTD and SSc have been reported 
(42), which is in accordance with the differences in the asso-
ciation between IgG anti-HDL-PON1 axis and disease-related 
autoantibodies herein reported.
Another interesting finding from our study is the emergence 
of anti-HDL antibodies in gut-related diseases. Increased levels 
of anti-HDL antibodies were found in IBD, comparable to those 
in systemic autoimmune diseases. An increased CVD risk has 
been documented in IBD (43), especially during disease flares 
(44), hence suggesting the involvement of immune-driven 
mechanisms. However, although impaired lipid levels (45) and 
PON1 activity (46) have been reported in IBD, the underly-
ing mediators are yet to be defined. Our findings expand the 
current knowledge in this scenario demonstrating a connec-
tion between anti-HDL and PON1 functionality in IBD. The 
differences in anti-HDL levels between ulcerative colitis (UC) 
and Crohn disease mirror that of the prevalence of subclinical 
atherosclerosis burden (47) and may be attributed to the shift 
toward Th2-response and humoral immunity present in UC 
compared to Crohn (48). Interestingly, HDL dysfunction in 
Crohn was similar to that of CD, in accordance with shared 
immunopathological features between these disorders (49). CD 
patients exhibited no increased anti-HDL levels, despite show-
ing a notable impairment in PON1 activity and an increased 
pro-oxidant status. However, the alterations in PON1, TAC, 
and HDL levels were counteracted by a strict gluten-free diet, 
in parallel with a reduction of anti-TGA titers. Taken together, 
these findings may underlie the beneficial effects of a gluten-free 
diet on CVR factors in CD (50), something worth keeping in 
mind in clinical practice.
anti-hDl antibodies and lipoprotein 
Dysfunction: a Translational approach  
for the clinical setting
CVR stratification and management in immune-driven diseases is 
suboptimal (51). A major criticism in the management approach 
over time has been the lack of a more holistic approach to patient 
care and a more index disease-centric care, with less attention 
to comorbid conditions or CVR. Moreover, the lack of a strong 
interphase between primary and secondary care, clinical pressures 
and health service infrastructures that challenge the management 
of factors and conditions beyond the index disease, along with 
routine unavailability of advanced imaging techniques for CVR 
stratification, all negatively influence the management of these 
conditions. Furthermore, available tools for CVR assessment 
have been demonstrated to be insufficient in systemic diseases 
(1, 52), as they are solely based on traditional CVR factors, hence 
emphasizing the urgent need of additional biomarkers. Taking 
into account our findings, anti-HDL antibodies may potentially 
represent a useful biomarker for addressing this unmet clinical 
need. Anti-HDL antibodies may improve the CVR management 
by identifying patients where lipoprotein dysfunction is observed 
FigUre 4 | Overview of the study findings: clinical relevance. Conventional clinical CVR management provides a suboptimal risk stratification, since only a partial 
estimation of the actual risk is achieved. Anti-high-density lipoprotein (HDL) antibodies may cover this unmet clinical need, as they are able to account, at least in 
part, for the lipoprotein dysfunction. Depending on the role of anti-HDL and disease-related autoantibodies, four different scenarios can be proposed, hence 
providing a rationale for personalized medicine approaches to improve the current standards of care in these conditions.
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and thus, capturing this pathological feature. Importantly, anti-
HDL levels can be measured through conventional, operator-
independent, and automatized laboratory techniques, hence 
representing a cost-effective option.
Overall, our findings delineate four different scenarios related 
to four different associations between the role of autoantibodies 
with the lipid profiles and HDL dysfunction. One scenario is 
composed by those diseases where lipoprotein dysfunction is 
solely associated with anti-HDL antibodies, such as MCTD or 
AAV. Previous results from our group and others suggest similar 
conclusions in SLE and RA (20, 22–24), with anti-HDL but 
not disease-related autoantibodies being associated with HDL 
dysfunction, indicating that this scenario may be restricted to 
systemic autoimmune diseases. Another group can be consid-
ered for diseases where blood lipid outcomes are determined 
by both anti-HDL and disease-related autoantibodies, such as 
IBD/UC or SSc. Moreover, some conditions exhibit alterations 
in the blood lipids that are only associated with disease-related 
autoantibodies, like IBD/Crohn or DM1. Finally, an independ-
ent group can be considered for those diseases where other 
(non-autoimmune) mechanisms are linked to HDL dysfunction, 
such as CD.
The fact that different scenarios can be delineated paves 
the ground for the implementation of tailored strategies to 
complement the currently available CVR stratification strategies 
(Figure  4). Including a screening of anti-HDL antibodies in 
systemic diseases (first group) would be advisable to improve 
CVR stratification. Similarly, anti-HDL assessment together 
with disease-related autoantibodies should be performed in 
the second group of patients. On the contrary, a tight control 
of disease features, including disease-related autoantibod-
ies screening, should be performed in the third group, since 
anti-HDL antibodies seem to not play a significant role. These 
different scenarios are in line with the concept of personalized 
medicine which is particularly relevant in those with complex 
clinical needs (Figure 4).
A number of limitations of the present report must be 
remarked. This study was designed as a proof of concept study to 
analyze the prevalence of anti-HDL antibodies in a wide range of 
immune-driven conditions beyond SLE and RA. Consequently, 
an in-depth analysis of the anti-HDL levels and specific clinical 
features or co-existing traditional CV risk factors in each con-
dition was not conceived and surrogate markers of CVD were 
not evaluated in our analyses. Finally, the data did not allow for 
analysis of the treatments received in each group of patients. 
However, although this may be considered as a limitation, early 
studies by our group and others showed no major effects of 
immunomodulatory treatments (22–24, 53).
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